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Introduction
Ankylosing spondylitis (AS) is a seronegative spondy-
loarthropathy that is frequently associated with human
leucocyte antigen (HLA)-B27; 90% of AS patients test
HLA-B27 positive. HLA-B27 physiologically binds anti-
genic peptides and thus presents them to CD8+ T lym-
phocytes. Single HLA-B27 restricted cytotoxic T
lymphocytes (CTLs) have been described in AS patients
with specificity for arthritogenic bacteria, viral peptides or
autoantigens such as peptides derived from the HLA-B27
molecule itself [1–3]. CTLs have been reported to main-
tain the inflammatory process even after the eradication of
the microbial pathogen by antimicrobial immune
responses [4].
In vivo, MHC-class I restricted CD8+ T cells are clonally
expanded and use various αβ T cell-receptors [5,6]. Some
of these CD8+ T cell clones represent even more than 50%
of all CD8+ T cells in single AS patients [7–9]. This oligo-
clonal population which recognizes specific MHC-class I /
antigen complexes is characterized by a distinct CD28–
CD57+ CD11ahigh phenotype [10]. The presence of this
oligoclonal CD28– population in a larger cohort of AS
patients has not been examined before. It has been sug-
gested, therefore, that the amount of CD8+ CTLs in a
peripheral blood sample can be estimated by determining
the percentage of CD8+ CD28– T cells. Furthermore, identi-
fication of CD8+ CTLs by the lack of CD28 has provided a
helpful tool to investigate this lymphocyte subset in healthy
Abstract
Circulating CD8+ CD28– T cells were found to be expanded more in patients with ankylosing
spondylitis than in an age-matched healthy population (41.2 ± 17.7% versus 18.6 ± 7.6%). The level
of CD8+ CD28– T cells was dependent on the disease status, but was independent of age. Most of
the CD8+ CD28– T cells produced perforin after stimulation in vitro, in contrast to their CD8+ CD28+
counterparts. From the clinical perspective, the percentage of the cytotoxic CD8+ CD28– T cells
reflected a more severe course of disease, as it correlated with distinct movement restrictions, as well
as the metrology score summarizing cervical rotation (in sitting position), chin-to-jugulum distance,
thoracic Schober, chest expansion, and fingers-to-floor distance (P = 0.032).
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subjects and patients with various diseases [11]. In the
healthy population, CD8+ CD28– T cells are not present at
birth, and the percentage of CD8+ CD28– T cells increases
with age [12–14]. This increase of CD8+ CD28– cells,
together with reduced circulating naive CD8+ T cells corre-
lates with immunodeficiency during aging [15,16]. As CD8+
CD28– T cells have shortened telomeres, they may have
reached a state of replicative senescence [17]. The ques-
tion as to whether such accelerated senescence is a conse-
quence of viral infections remains open. There may be a role
for Epstein–Barr virus (EBV) in the pathogenesis of AS, as
different HLA-B27 subtypes are able to present the same
EBV peptide [1]. Hyper-responsiveness to EBV has also
been observed in AS patients [18]. Irrespective of EBV,
CD8+ CD28– T cells are markedly expanded in
cytomegalovirus (CMV) seropositive healthy individuals and
seropositive patients with rheumatoid arthritis [19,20].
The aim of this study was to quantify the CD8+ CD28–
compartment in a cohort of AS patients in comparison
with a healthy control group, and to correlate the level of
these cells with clinical parameters of disease progression
and seropositivity to EBV and CMV.
Materials and methods
Patient population
Patients with definite AS (as defined by the modified New
York criteria [21]) were recruited from the Gasteiner Heil-
stollen Hospital (Bad Gastein-Böckstein, Austria). A total
of 95 patients with definite AS (13.7% female) and 53
healthy volunteers (45.3% female) were enrolled in the
study (for patients’ characteristics see Supplementary
Table 1). In the controls, acute or chronic inflammatory
diseases were excluded by physical examination and
detailed history. Patients and controls did not differ in age
(49.1 ± 11.4 versus 48.0 ± 14.0 years, respectively).
Forty-five AS patients did not take any medication, the
others took nonsteroidal anti-inflammatory drugs (n = 47),
corticosteroids (n = 8), sulfasalazine (n = 2) or azathioprin
(n = 1). Patients with multiple drug intakes were consid-
ered in all groups separately.
Immunostaining and flow cytometry
Surface staining of peripheral blood mononuclear cells
was performed using FITC-conjugated anti-CD8, phyco-
erythrin-conjugated anti-CD28 and peridinin-chlorophyll-
protein-conjugated anti-CD3 or anti-CD8 monoclonal
antibodies (Becton Dickinson, San Diego, CA). For intra-
cellular detection of perforin or interferon-γ (IFN-γ), stimu-
lated cells were stained for their surface antigens, CD28
and CD8, and with FITC-conjugated anti-perforin, anti-IFN-γ
or control immunoglobulin, respectively.
Serological assays
Investigators assessing EBV- and CMV-seropositivity
were blinded to the sera of 30 AS patients of different
ages, with variable percentages of CD8+ CD28– cells.
Anti-EBV and anti-CMV IgG antibodies were determined
according to the manufacturer’s instructions using ELISA
kits from Aventis Behring (Vienna, Austria).
Statistical analysis
The Mann–Whitney test, the two-sided Pearson test and
regression analysis by ANOVA were performed using the
SPSS program, version 10.0 (Chicago, IL, USA). Bonfer-
roni adjustment was performed in case of multiple testing.
Results
Prevalence of CD8+ CD28– T cells in AS patients and
controls
Peripheral blood from 95 AS patients and 53 healthy con-
trols was analyzed by flow cytometry for the presence of
CD28– cells in the CD3+ CD8+ compartment. The per-
centage of CD3+ CD8+ T cells lacking the co-stimulatory
marker CD28 was significantly increased in all AS patients
compared to their age-matched healthy controls (Fig. 1).
In AS patients, the mean of the percentage of CD8+
CD28– T cells was 41.1 ± 17.7%, compared to
18.6 ± 7.6% in the healthy controls (P < 0.0001). This
increase of CD8+ CD28– T cells was paralleled by a
decrease of the CD8+ CD28+ subset. When the level of
30% CD8+ CD28– T cells was selected as a cut-off value,
68.4% of the AS patients, but only 9.4% of the healthy
controls had higher levels than the cut-off value.
Figure 1
Accumulation of CD8+ CD28– cells in peripheral blood mononuclear
cells of 95 patients with ankylosing spondylitis (AS) () and 53 age-
matched healthy controls (). Cells were stained with fluorescence-
marked antibodies directed against CD3, CD8 and CD28 and flow
cytometry was used to count CD3+, CD8+, CD28+ and CD28– cells.
The Mann–Whitney test was used to determine the statistical difference
between patients and the healthy control group. * P < 0.001.
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100The finding of elevated levels of CD8+ CD28– T cells was
independent of the patients’ age (Fig. 2a). Regression
lines were calculated as y = 0.2x + 30.6 for AS patients
(R2 = 0.019) and y = 17.1 for the healthy controls
(R2 = 0.003). In the ANOVA regression model AS
disease, but not age, was an independent parameter for
increased levels of CD8+ CD28– T cells. In receiver oper-
ating curves (ROC), the areas under the curve were calcu-
lated to be 0.861 for AS disease and 0.545 for age
(Fig. 2b).
Perforin and interferon-γ γ production by CD8+ CD28–
T cells
For functional characterization of CD8+ CD28– T cells in
AS patients, flow cytometric single cell analysis was used,
and the intracellular accumulation of perforin and IFN-γ
were compared between CD28+ T cells and CD28–
CD8+ T cells. Production of perforin was more frequent in
CD28– CD8+ T cells (83.9 ± 17.3% versus 1.6 ± 1.2%
stained with IgG control antibodies) than in their CD28+
counterparts (21.3 ± 12.0% versus 3.8 ± 1.8% stained
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Figure 2
Age dependence of the percentages of CD8+ CD28– T cells in the peripheral blood. (a) The levels of CD8+ CD28– T cells are shown in correlation
with age. Regression lines were calculated for patients with ankylosing spondylitis (AS) (, unbroken line) and healthy controls (, dashed line).
(b) A regression model was applied to determine the possible effects of AS disease and age on the level of peripheral CD8+ CD28– T cells.
Receiver operating curves (ROC) and the area under the curve (AUC) were determined for both independent parameters.
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0.00 1.00 0.75 0.50 0.25with IgG control antibodies) (P < 0.001) (Fig. 3a). Produc-
tion of IFN-γ was more frequent in CD28– CD8+ T cells
(61.4 ± 10.1% versus 0.35 ± 0.0% stained with IgG
control antibodies) than in their CD28+ counterparts
(30.9 ± 3.2% versus 0.6 ± 0.2% stained with IgG control
antibodies) (P < 0.001) (Fig. 3b).
The dependencies of CD8+ CD28– T cells on clinical
variables
Using the two-sided Pearson test and Bonferroni adjust-
ment because of multiple testing, a trend of a correlation
was obtained between the percentage of CD8+ CD28– T
cells and cervical rotation (in sitting position) (P = 0.165)
(see Supplementary Table 2). Based on these results and
clinical experience, a metrology index was calculated sum-
marizing cervical rotation (in sitting position), chin-to-
jugulum distance, thoracic Schober, chest expansion, and
fingers-to-floor distance. There was a significant correla-
tion of this index with the percentage of CD8+ CD28– T
cells, but not for the scores for the Health Assessment
Questionnaire (HAQ-S), Bath Ankylosing Spondylitis
Functional Index (BASFI) or Bath Ankylosing Spondylitis
Metrology Index (BASMI) (P = 0.032 for the metrology
index, after Bonferroni adjustment for multiple testing,
Fig. 4) [22–24]. No correlation was found between the
percentage of CD8+ CD28– T cells and the erythrocyte
sedimentation rate, blood counts, disease duration or time
since onset of symptoms.
Lack of association with serological EBV- and CMV-
seropositivity
Of the AS patients tested, 96.7% were positive for EBV-
IgG and 60% were positive for CMV-IgG. Levels of CD8+
CD28– T cells were independent of seropositivity of CMV
and EBV. Levels of CD8+ CD28– T cells did not differ
between patients who were positive or negative for CMV-
IgG (39.4 ± 23.1% and 38.6 ± 21.1%, respectively). The
CMV-IgG negative AS patients showed levels of CD8+
CD28– T cells ranging up to 77.32%. The only patient
who was seronegative for EBV was seropositive for CMV,
and had 60.0% CD28– T cells in the CD8+ compartment.
Assuming a cut-off level of 30% between normal and
pathological percentages of CD8+ CD28– T cells, we did
Arthritis Research    Vol 4 No 1 Schirmer et al.
Figure 3
Intracellular production of perforin and interferon-γ in CD8+ CD28– and
CD28+ T cells. Peripheral blood mononuclear cells of patients with
ankylosing spondylitis were stimulated with phorbol 12-myristate 13-
acetate and ionomycin in the presence of brefeldin A. Cells were
stained with fluorescence-marked monoclonal antibodies (mAbs)
directed against CD8, CD28 and either perforin or interferon-γ and
counted by flow cytometry. Whiskers boxblots show the results of 5
independent experiments for perforin (a) and 6 experiments for
interferon-γ (b) with 50 % of cases within the boxes and 80 %
between the endpoints of the whiskers (lines). The Mann–Whitney test
was used to determine the statistical difference between the
percentage of perforin-positive or interferon-γ-positive CD28+ and
CD28– cells out of the CD8+ T cell compartment (each with
P < 0.001).
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Figure 4
Disease status of ankylosing spondylitis (AS) and percentages of
CD8+ CD28– T cells. AS patients were subdivided into groups with
low, medium and high grades of movement restriction by a metrology
index which includes cervical rotation, chin-to-jugulum distance,
thoracic Schober, chest expansion, and the fingers-to-floor distance.
Whiskers boxblots show 50% of cases within the boxes and 80%
between the endpoints of the whiskers (lines). The two-sided Pearson
test (with subsequent Bonferroni adjustment due to multiple testing)
was used to assess statistical significance. * P = 0.032.
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–not find a difference in either CMV-specific or EBV-spe-
cific IgG titers between patients with low and high levels
of CD8+ CD28– T cells (see Supplementary Fig. 1).
Discussion
Circulating CD8+ CD28– T cells (characterized by a lack
of the CD28 co-stimulatory molecule on the cell surface
and production of perforin) are increased not only in
various infectious diseases but also in patients with
autoimmune diseases like AS. The fact that the accumula-
tion of CD8+ CD28– T cells correlated with anatomical
restrictions of the joints routinely measured in AS patients
further underlines the pathogenic relevance in AS. This
metrology index, as well as the established BASMI score,
quantify anatomical restrictions of joints, whereas the
HAQ-S and the BASFI scores include more complex
restrictions of daily life activities. We believe that a spe-
cific metrology index might be the best tool to describe
disease status as an integral function of disease duration
and activity. This could explain why the percentage of
CD8+ CD28– T cells in AS patients reflects the anatomi-
cal restrictions and status of disease, but not functional
and life quality restrictions. In our study, the levels of CD8+
CD28– T cells were not correlated with the age of the
subjects, whereas others had observed an accumulation
of CD8+ CD28– T cells in the elderly, including centenari-
ans [12–14]. Clonal populations known to be part of the
CD28– compartment have been discussed earlier as a
T cell equivalent of benign monoclonal gammopathy [25].
Our results can be explained by the fact that 83% of our
controls were younger than 60 years and all of them were
preselected for the absence of acute or chronic inflamma-
tory disease.
In view of the different functions of CD8+ CD28– T cells, it
is difficult to propose a specific role for these cells in AS.
CD8+ CD28– T cells have been reported to be effector
cells, producing perforin, granzyme B, tumour necrosis
factor-α and IFN-γ [10,26–29], although others have
reported only low levels of tumour necrosis factor-α and
IFN-γ in unselected CD8+ T cells from AS patients [30].
Our data confirms a possible role of IFN-γ in the patho-
genesis of AS. The CD8+ CD28– T cells contain clonally
expanded CTLs specific for human CMV or with unknown
antigen-specificity [31], and act as suppressor cells on
antigen-presenting cells, inhibiting their ability to elicit
T helper cell activation and proliferation [32]. The periph-
eral increment of CTLs may develop as a consequence of
an oligoclonal outgrowth of CD8+ CD28– T cells during
the course of the disease [33], or by CD8+ CD28+ T cells
preferentially migrating to peripheral sites [14].
The role of prior EBV- or CMV-infection in AS and periph-
eral accumulation of CD8+ CD28– T cells is still unclear.
Clonally expanded CD8+ T cells reactive against these
viruses are frequently present in chronic inflammatory
lesions [34]. In rheumatoid arthritis patients, CMV-
seropositivity has been directly correlated with increased
levels of CD8+ CD28– T cells [20]. It may be argued,
however, that patients with more severe rheumatoid arthri-
tis disease and higher levels of CD8+ CD28– T cells have
undergone more consistent immunosuppressive therapy
and thus have an iatrogenic risk for CMV and EBV infec-
tions. Most of our AS patients, however, cannot be con-
sidered to be immunosuppressed, except for the fact that
their immune system is disturbed by the underlying
disease. As a considerable number of AS patients tested
seronegative for CMV, but showed an accumulation of
CD8+ CD28– T cells in the peripheral blood, the two phe-
nomena appear to be independent of each other in AS
patients.
Conclusions
Cytotoxic CD28– T cells accumulate in the circulating
CD8+ T cell population of AS patients and are associated
with more severe anatomical joint restrictions. In AS
patients, occurrence of CD8+ CD28– T cells is indepen-
dent of prior CMV infection.
Acknowledgements
The study was supported by the Verein zur Förderung der Hämatolo-
gie, Onkologie und Immunologie (Innsbruck, Austria) and by the
Gasteiner Heilstollen GesmbH (Badgastein, Austria). We want to thank
Ms. Rajam Csordas (PhD, Oxon) for her help in preparing the manu-
script.
References
1. Brooks JM, Murray RJ, Thomas WA, Kurilla MG, Rickinson AB:
Different HLA-B27 subtypes present the same immunodomi-
nant Epstein-Barr virus peptide. J Exp Med 1993,  178:879-
887.
2. Hermann E, Yu DTY, Meyer zum Büschenfelde KH, Fleischer B:
HLA-B27-restricted CD8 T cells derived from synovial fluids
of patients with reactive arthritis and ankylosing spondylitis.
Lancet 1993, 342:646-650.
3. Fiorillo MT, Maragno M, Butler R, Dupuis ML, Sorrentino R:
CD8(+) T-cell autoreactivity to an HLA-B27-restricted self-
epitope correlates with ankylosing spondylitis. J Clin Invest
2000, 106:47-53.
4. Hermann E, Fleischer B, Meyer zum Büschenfelde KH: Bacteria-
specific cytotoxic CD8+ T cells: a missing link in the patho-
genesis of the HLA-B27-associated spondylarthropathies.
Ann Medicine 1994, 26:365-369.
5. Liu Z, Tugulea S, Cortesini R, Suciu-Foca N: Specific suppres-
sion of T helper alloreactivity by allo-MHC-class I restricted
CD8+ CD28– T cells. Intl Immunol 1998, 10:775-783.
6. Pennesi G, Liu Z, Ciubotariu R, Jiang S, Colovai A, Cortesini R,
Suciu-Foca N, Harris P: TCR repertoire of suppressor CD8+
CD28– T cell populations. Human Immunol 1999, 60:291-304.
7. Posnett DN, Gottlieb A, Bussel JB, Friedman SM, Chiorazzi N, Li
Y, Szabo P, Farid NR, Robinson MA: T cell antigen receptors in
autoimmunity. J Immunol 1988, 141:1963-1969.
8. Grunewald J, Jeddi-Tehrani M, Dersimonian H, Andersson R,
Wigzell H: A persistent expansion in the peripheral blood of a
normal adult male: a new clinical entity? Clin Exp Immunol
1992, 89:279-284.
9. Fitzgerald JE, Ricalton NS, Meyer AC, West SG, Kaplan H,
Berendt C, Kotzin BL: Analysis of clonal CD8+ T cell expan-
sions in normal individuals and patients with rheumatoid
arthritis. J Immunol 1995, 154:3538-3547.
10. Azuma M, Phillips JH, Lanier LL: CD28- T lymphocytes. Anti-
genic and functional properties. J Immunol 1993, 150:1147-
1159.
Available online http://arthritis-research.com/content/4/1/071
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
r
e
s
e
a
r
c
h
 
a
r
t
i
c
l
e11. Speiser DE, Valmori D, Rimoldi D, Pittet ML, Lienard D, Cerun-
dolo V, Mac Donald HR, Cerottini J-C, Romero P: CD28 – nega-
tive cytolytic effector T cells frequently express NK receptors
and are present at variable proportions in circulating lympho-
cytes from healthy donors and melanoma patients. Eur J
Immunol 1999, 29:1990-1999.
12. Fagnoni FF, Vescovivi R, Mazzola M, Bologna G, Nigro E,
Lavagetto G, Franceschi C, Passeri M, Sansoni P: Expansion of
cytotoxic CD8+  CD28–  T-cells in healthy ageing people,
including centenarians. Immunology 1996, 88:501-507.
13. Merino J, Martinez-Gonzalez MA, Rubio M, Inoges S, Sanchez-
Ibarrola A, Subira ML: Progressive decrease of CD8high+
CD28+ CD57- cells with ageing. Clin Exp Immunol 1998, 112:
48-51.
14. Nociari MM, Telford W, Russo C: Postthymic development of
CD28– CD8+ T cells subset: Age-associated expansion and
shift from memory to naive phenotype. J Immunol 1999, 162:
3327-3335.
15. Bandres E, Merino J, Vazquez B, Inoges S, Moreno C, Subira ML,
Sanchez-Ibarrola A: The increase of IFN-gamma production
through aging correlates with the expanded CD8(+high)
CD28(-) CD57(+) subpopulation. Clin Immunol 2000, 96:230-
235.
16. Fagnoni FF, Vescovini R, Passeri G, Bologna G, Pedrazzoni M,
Lavagetto G, Casti A, Franceschi C, Passeri M, Sansoni P: Short-
age of circulating naive CD8(+) T cells provides new insights
on immunodeficiency in aging. Blood 2000, 95:2860-2868.
17. Monteiro J, Batliwalla F, Ostrer H, Gregersen PK: Shortened
telomeres in clonally expanded CD28- CD8+ T cells imply a
replicative history that is distinct from their CD28+  CD8+
counterparts. J Immunol 1996,156: 3587-3590.
18. Winrow VR, Perry JD: Hyper-responsiveness to EBV in anky-
losing spondylitis. Ann Rheum Dis 1987, 46:493-494.
19. Gratama JW, Naipal AM, Oosterveer MA, Stijnen T, Kluin-Nele-
mans HC, Ginsel LA, den Ottolander GJ, Hekker AC, D’Amaro J,
van der Giessen M, Tanke HJ: Effects of herpes virus carrier
status on peripheral T lymphocyte subsets. Blood 1987, 70:
516-523.
20. Hooper M, Kallas EG, Coffin D, Campbell D, Evans TG, Looney
RJ:  Cytomegalovirus seropositivity is associated with the
expansion of CD4+ CD28- and CD8+ CD28- T cells in
rheumatoid arthritis. J Rheumatol 1999, 26:1452-1457.
21. van der Linden S, Valkenburg HA, Cats A: Evaluation of diag-
nostic criteria for ankylosing spondylitis. A proposal for modi-
fication of the New York criteria. Arthritis Rheum 1984,  27:
361-368.
22. Abbott CA, Helliwell PS, Chamberlain MA: Functional assess-
ment in ankylosing spondylitis: evaluation of a new self-
administered questionnaire and correlation with anthro-
pometric variables. Br J Rheumatol 1994, 33: 1060-1066.
23. Jenkinson TR, Mallorie PA, Whitelock HC, Gail Kennedy L,
Garrett SL, Calin A: Defining spinal mobility in ankylosing
spondylitis (AS). The Bath AS Metrology Index. J Rheumatol
1994, 21: 1694-1698.
24. Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie
P, Jenkinson T: A new approach to defining functional ability in
ankylosing spondylitis: the development of the Bath Ankylos-
ing Spondylitis Functional Index. J Rheumatol 1994, 21:2281-
2285.
25. Posnett DN, Sinha R, Kabak S, Russo C: Clonal population of T
cells in normal elderly humans: the T cell equivalent to
“benign monoclonal gammopathy”. J Exp Med 1994, 179:609-
618.
26. Berthou C, Legros-Maida S, Soulié A, Wargnier A, Guillet J,
Rabian C, Gluckman E, Sasportes M: Cord blood T lympho-
cytes lack constitutive perforin expression in contrast to adult
peripheral blood T lymphocytes. Blood 1995, 85:1540-1546.
27. Hamann D, Baars PA, Rep MH, Hooibrink B, Kerkhof-Garde SR,
Klein MR, van Lier RA: Phenotypic and functional separation of
memory and effector human CD8+ T cells. J Exp Med 1997,
186:1407-1418.
28. Posnett DN, Edinger JW, Manavalan JS, Irwin C, Marodon G: Dif-
ferentiation of human CD8 T cells: implications for in vivo per-
sistence of CD8+ CD28– cytotoxic effector clones. Int Immunol
1999, 11:229-241.
29. Borthwick NJ, Lowdell M, Salmon M, Akbar AN: Loss of CD28
expression on CD8+ T cells is induced by IL-2 receptor γ γ
chain signalling cytokines and type I IFN, and increases sus-
ceptibility to activation-induced apoptosis. Int Immunol 2000,
12:1005-1013.
30. Rudwaleit M, Siegert S, Yin Z, Eick J, Thiel A, Radbruch A, Sieper
J, Braun J: Low T cell production of TNFα α and IFNγ γ in ankylos-
ing spondylitis: its relation to HLA-B27 and influence of the
TNF-308 gene polymorphism. Ann Rheum Dis 2001, 60:36-42.
31. Weekes MP, Wills MR, Mynard K, Hicks R, Sissons JG,
Carmichael AJ: Large clonal expansions of human virus-spe-
cific memory cytotoxic T lymphocytes within the CD57+
CD28– CD8+ T-cell population. Immunology 1999, 98:443-449.
32. Li J, Liu Z, Jiang S, Cortesini R, Lederman S, Suciu-Foca N: T
suppressor lymphocytes inhibit NF-κ κB-mediated transcrip-
tion of CD86 gene in APC. J Immunol 1999, 163:6386-6392.
33. Duchmann R, Lambert C, May E, Hohler T, Marker-Hermann E:
CD4+ and CD8+ clonal T cell expansions indicate a role of
antigens in ankylosing spondylitis; a study in HLA-B27+
monozygotic twins. Clin Exp Immunol 2001, 123:315-322.
34. Scotet E, Peyrat MA, Saulquin X, Retiere C, Couedel C,
Davodeau F, Dulphy N, Toubert A, Bignon JD, Lim A, Vie H, Hallet
MM, Liblau R, Weber M, Berthelot JM, Houssaint E, Bonneville M:
Frequent enrichment for CD8 T cells reactive against
common herpes viruses in chronic inflammatory lesions:
towards a reassessment of the physiopathological signifi-
cance of T cell clonal expansions found in autoimmune
inflammatory processes. Eur J Immunol 1999, 29:973-985.
Supplementary material
Materials and methods
Patient population
Patients underwent routine evaluation by experienced
rheumatologists. Clinical assessment included time since
onset of symptoms, duration of disease, measurements of
typical ankylosing spondylitis (AS)-specific parameters
and scores including the Health Assessment Question-
naires (HAQ-S, n = 55), the Bath Ankylosing Spondylitis
Metrology Index (BASMI, n = 55) and the Bath Ankylosing
Spondylitis Functional Index (BASFI, n = 75) (Supplemen-
tary Table 1). All patients were screened for blood counts
and erythrocyte sedimentation rate, and after informed
consent, 15 ml of peripheral blood was obtained for flow
cytometric studies and serology.
Immunostaining and flow cytometry
Peripheral blood mononuclear cells were isolated by Ficoll
density gradient centrifugation. Surface staining of periph-
eral blood mononuclear cells was performed using FITC-
conjugated anti-CD8, phycoerythrin-conjugated anti-CD28
and peridinin chlorophyll protein-conjugated anti-CD3 or
anti-CD8 monoclonal antibodies, respectively (Becton
Dickinson, San Diego, CA). Cells were simultaneously
stained for 30 minutes at 4°C and, after washing with
phosphate-buffered saline, fixed with 4% paraformalde-
hyde in phosphate-buffered saline for 60 minutes. For
intracellular detection of perforin or IFN-γ, cells were stim-
ulated with 25 ng/ml phorbol 12-myristate 13-acetate and
1 µg/ml ionomycin in the presence of 10 µg/ml brefeldin A
for four hours (Sigma, St. Louis, MO). Cells were then
stained for their surface antigens CD28 and CD8 and,
after permeabilization, with FITC-conjugated anti-perforin,
anti-IFN-γ or control immunoglobulin, respectively. Fixed
Arthritis Research    Vol 4 No 1 Schirmer et al.cells were analyzed on a FACS-Calibur flow cytometer
(Becton Dickinson). Data were analyzed using WinMDI
software (Joseph Trotter, Scripps Research Institute, La
Jolla, CA).
Statistical analysis
The Mann–Whitney test was used to compare the per-
centages of CD8+ CD28– T cells between AS patients
and healthy controls, the percentages of perforin or IFN-γ
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Supplementary Figure 1
Epstein–Barr virus (EBV)-IgG and cytomegalovirus (CMV)-IgG titers in
patients with ankylosing spondylitis (AS). AS patients were grouped
according to the carrier status of circulating CD8+ CD28– T cells.
Carrier status was defined as expressing >30% CD8+ CD28– T cells.
IgG titers were determined by ELISA. No differences were seen.
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Supplementary Table 2
Percentages of CD8+ CD28– T cells in patients with ankylosing spondylitis, classified according to the grade of their movement
restriction
CD8+ CD28– T cells in patients (%)
Minor Mean Major
Cervical rotation (sitting) 34.2 ± 17.3 45.0 ± 18.1 44.1 ± 16.3
Cervical rotation (lying) 36.9 ± 18.1 48.8 ± 15.3 44.7 ± 15.6
Tragus to wall 44.1 ± 17.2 41.8 ± 18.0 44.4 ± 16.5
Chin to jugulum 34.7 ± 18.2 43.5 ± 17.5 45.1 ± 16.3
Head to wall 39.8 ± 16.8 44.6 ± 18.6 40.5 ± 18.6
Chest expansion 35.5 ± 15.0 43.7 ± 18.9 43.2 ± 17.6
Thoracic Schober 39.3 ± 16.6 41.4 ± 18.7 42.8 ± 17.9
Modified Schober 41.0 ± 18.3 45.2 ± 15.3 43.7 ± 17.7
Lumbar side flexion 39.3 ± 16.3 45.5 ± 18.1 44.6 ± 16.9
Fingers to floor 36.8 ± 16.4 42.8 ± 18.8 43.9 ± 17.8
Intermalleolar distance 39.8 ± 17.4 44.5 ±16.9 45.2 ± 17.2
Patients were grouped in those with minor restrictions (head-to-wall distance <5, chin-to jugulum distance <3, cervical rotation in sitting position
>70, thoracic Schober >32, chest expansion >6 and fingers-to-floor distance <20), those with mean restrictions, and those with major
restrictions (head-to-wall distance >20, chin-to-jugulum distance >6, cervical rotation in sitting position <15, thoracic Schober <30.5, chest
expansion <2 and fingers-to-floor distance >50). Correlations between the level of CD8+ CD28– T cells and the extent of movement restrictions
were not significant (using Bonferroni adjustment after Pearson test).
Supplementary Table 1
Characteristics of patients in the study
Patient value Normal range
Duration of AS since  9.9 ± 9.3
diagnosis (years)
Time since onset of  16.6 ± 12.2
symptoms (years)
ESR (mm/hour) 31.4 ± 20.3 <15
Leucocytes (G/I) 9.08 ± 1.92 3.8–10.5
Erythrocytes (T/I) 4.88 ± 0.59 3.9–5.7
Platelets (G/I) 344 ± 99 140–345
HAQ-S score (0–3) 0.89 ± 0.51
BASFI (0–10) 4.67 ± 2.05
BASMI (0–10) 5.04 ± 2.20
AS, ankylosing spondylitis; BASFI, Bath Ankylosing Spondylitis
Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index;
ESR, erythrocyte sedimentation rate; HAQ-S = Health Assessment
Questionnaire; G/l, giga/liter; T/l, tara/liter.positive T cells between the CD8+ CD28+ and the CD8+
CD28– compartments, and the EBV- and CMV- IgG titers
of AS patients with less than and more than 30% of CD8+
CD28– T cells. The Pearson test (two-sided) was used to
examine the correlations between clinical measurements
or scores and the percentage of CD8+ CD28– T cells.
Regression analysis by ANOVA testing and ROC curves
were used to evaluate the dependence of the level of
CD8+ CD28– T cells on AS disease and age. Bonferroni
adjustment was performed in case of multiple testing. Sta-
tistical analysis was performed using the SPSS program,
version 10.0 (Chicago, IL, USA).
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